Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × genexol-PM × Breast × Clear all
NCT00876486 2017-05-01

Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

Samyang Biopharmaceuticals Corporation

Phase 3 Completed
213 enrolled
Breast

Breast Neoplasms

NCT02064829 2016-03-25

TRIBECA

Sorrento Therapeutics, Inc.

Phase NA Completed
111 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡